Compare VST & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VST | BDX |
|---|---|---|
| Founded | 1882 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1B | 51.5B |
| IPO Year | 2016 | 1995 |
| Metric | VST | BDX |
|---|---|---|
| Price | $165.60 | $155.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $234.09 | $186.92 |
| AVG Volume (30 Days) | ★ 3.8M | 2.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | 0.56% | ★ 2.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.18 | 1.34 |
| Revenue | $17,738,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $30.97 | N/A |
| Revenue Next Year | $8.79 | $2.22 |
| P/E Ratio | ★ $74.50 | $116.06 |
| Revenue Growth | 2.98 | ★ 8.24 |
| 52 Week Low | $103.34 | $152.79 |
| 52 Week High | $219.82 | $213.08 |
| Indicator | VST | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 37.77 |
| Support Level | $153.95 | $153.75 |
| Resistance Level | $172.93 | $159.71 |
| Average True Range (ATR) | 6.39 | 2.85 |
| MACD | 1.82 | 1.01 |
| Stochastic Oscillator | 94.63 | 35.45 |
Vistra Corp. is one of the largest power producers and retail energy providers in the USA. It owns 44 gigawatts of generation capacity, including natural gas (27 GW), nuclear (6.5 GW), coal (8.7 GW), and solar and battery storage (1.4 GW). The Cogentrix acquisition will add 5.5 GW of gas generation. Vistra's retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.